Jefferies cuts Clorox stock price target on cost pressures By Investing.com

Jefferies cut Clorox’s price target to $139 from $151 while keeping a Buy rating, citing ongoing cost pressures, commodity inflation, and continued market share losses. The firm expects Q3 organic sales growth to miss expectations by 50 bps and sees Clorox lowering fiscal 2026 EPS guidance; Jefferies also cut its fiscal 2026 and 2027 EPS estimates by 2% and 8%, respectively. Clorox’s recently completed GOJO acquisition expands its health and hygiene portfolio, but the near-term setup remains challenged.

Analysis

The key setup is not just another earnings warning; it’s the increasing probability that CLX enters a longer deleveraging cycle where margin repair and top-line stabilization cannot happen at the same time. With the stock already discounting a lot of bad news, the next leg is likely driven by whether management sounds willing to sacrifice volume to protect gross margin or vice versa — and either choice can keep the multiple pinned. The GOJO acquisition adds strategic optionality, but near term it is more likely to complicate integration, working capital, and synergy visibility than to offset core category weakness.

The second-order winner in a sustained CLX slowdown is the broader private-label and value segment: when a branded household essential loses shelf velocity, retailers tend to reallocate facings toward lower-price alternatives faster than consumers fully trade back. That dynamic is usually sticky for 2-3 quarters, not 2-3 weeks, because planogram resets and promo calendars lag demand deterioration. Input-cost inflation also creates a hidden benefit for larger competitors with better hedging, procurement scale, or broader mix, while smaller branded peers may be forced into margin-destructive promotions to defend share.

The market is likely underappreciating the duration risk. If commodity pressure persists into fiscal 2026 guidance, the real issue is not the next quarter’s EPS cut but whether consensus has to rebase the medium-term earnings power lower for multiple years, which would justify another de-rating even from near lows. The contrarian case is that the stock may be “cheap” only relative to peak-margin history; if management can frame 2027 as a clean inflection, the setup could become a sharp short-covering trade, but that requires evidence of share stabilization first.

For catalysts, watch the April 30 print for language on elasticities, promotion intensity, and whether management quantifies integration synergies from GOJO early enough to offset the cost narrative. In the near term, the stock is more sensitive to guidance commentary than reported EPS, and any further downward revisions from analysts can keep pressure on sentiment for 4-8 weeks. A decisive miss on organic sales would also likely pull capital out of the entire defensive consumer basket into cleaner-quality staples names.

Key Decisions for Investors

• Avoid catching the falling knife in CLX ahead of April 30; wait for guidance reset and evidence of sequential share stabilization before considering long exposure.
• For opportunistic traders, buy CLX May/June put spreads into the earnings window if implied volatility remains subdued; the risk/reward is favorable if management cuts FY26 outlook again.
• Pair trade: long higher-quality staples with pricing power versus short CLX over the next 1-3 months; the thesis is margin durability and cleaner earnings revision trends.
• If CLX trades meaningfully below the current low-$100 area without further fundamental deterioration, consider a tactical long only on confirmation that guidance is reset and the post-earnings selloff is exhausted; target a 10-15% mean-reversion bounce, not a structural re-rating.